|
Current issue
Archive
Videos
Articles in press
About the journal
Supplements
Editorial board
Reviewers
Abstracting and indexing
Subscription
Contact
Instructions for authors
Publication charge
Ethical standards and procedures
Editorial System
Submit your Manuscript
|
3/2012
vol. 114 abstract:
Original paper
Evaluation of treatment efficacy of intravitreal ranibizumab injections in patients with wet type of AMD
Wojciech Lubiński
1
,
Katarzyna Mozolewska-Piotrowska
1
,
Kamila Krasodomska
1
,
Krzysztof Penkala
2
,
Beata Kaźmierczak
1
,
Danuta Karczewicz
1
Online publish date: 2012/10/12
View
full text
Get citation
ENW EndNote
BIB JabRef, Mendeley
RIS Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
Purpose
To evaluate foveal function, retinal circulation and foveal thickness before and after intravitreal ranibizumab injections in eyes with wet type of age-related macular degeneration (AMD). Material and methods The study group consisted of 21 eyes (20 patients) with choroidal neovascularisation (CNV) due to AMD. Inclusion criteria were based on fluorescein angiography (FA) and distance best corrected visual acuity (DBCVA) – log MAR scale. In each eye, 3 consecutive injections of ranibizumab every 4 weeks were administered and then individual course for reinjections according to DBCVA and optical coherence tomography (OCT) up to 12 months was applied. At baseline, 3, 6 and 12 months follow-up, the following tests were performed: DBCVA, multifocal electroretinogram (mfERG) and OCT. Additionally, FA was carried out before the treatment, 3 and 12 months from the baseline. Results At baseline, FA revealed mainly minimally occult choroidal neovascularisation – 57% (12/21) of eyes. At 3 months choroidal neovascularisation diameter was stable; no leakage from active choroidal neovascularisation was seen in 76% (16/21) of eyes. After 12 months follow-up, increase in choroidal neovascularisation diameter was seen in 43% (9/21) of eyes and no leakage in 57% (12/21) of cases. The mean DBCVA significantly improved only after 3 months (p<0.02). Significant decrease of mean foveal thickness was observed in each follow-ups (p<0.01). The mfERG data from the macular region remained stable or improved slightly in some cases. Conclusions In our series of patients with the wet type of AMD after intravitreal injections of ranibizumab in 12 months follow- -up, the reduction of foveal thickness was noted while DBCVA and the bioelectrical function from the macular region measured by the mfERG remained stable. |
|
POLSKI
